Insider buying last 90 days
No open-market insider purchases were filed for CLMT in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Calumet reported record third-quarter 2026 results this week, with net income of $273.3 million and Adjusted EBITDA with Tax Attributes of $347.2 million, driven by strength in Specialty Products & Solutions and record earnings from Montana Renewables. Earnings per share of $2.910 topped a consensus estimate of $1.550, with one report citing $4.65 per share against a $1.21 consensus, and revenue reached $1.68 billion versus an estimated $1.26 billion. The company also continued deleveraging, retiring about $265 million of debt since July, though management noted the specialty supply windfall may not represent a new norm.
Despite the beat, the stock closed at $36.06, down 9% on the day and sitting between its 50-day average of $53.18 and 200-day average of $39.19, with one-month returns of -36.1% and one-year returns of 84.8%. The GekkoIndex reads 78.5, placing it in the Buying zone, and the price stands 15.4% below Gekko Fair Value of $42.62.
Over the next 20 trading days, the next earnings date falls on 26 February 2027, outside a typical holding window. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows, though two trailblazer holders are noted. Seasonality from this point has averaged a 5.1% gain over 5 years, rising in 4 of them. Analyst consensus among 5 firms carries a target of $55.8, worth noting alongside the stock's typical 20-day move of 9.6%.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Calumet scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
Averages disagree
Close $34.30 sits between the 50-day ($51.86) and 200-day ($39.46) averages, or the averages disagree.
See the chart71.9, Buying
Reading 71.9 is in the Buying zone.
See the GekkoIndex16.5% below
Price is 16.5% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 103 days
Next report Feb 26, 2027, 103 days away — outside a typical 20-trading-day hold.
See earnings+1.4% on average
From this point in the calendar, the next 20 trading days averaged +1.4% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Calumet closed at $34.30 on Nov 13, 2026, +81.2% over the past year, inside a 52-week range of $17.85 to $59.87.
Use the left and right arrow keys to read daily values.
Put CLMT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Calumet makes and sells specialty branded products along with renewable fuel, combining formulation work with manufacturing to serve customers who need tailored fuel and product solutions. Among its recognizable offerings are brands such as Royal Purple, Bel-Ray, and TruFuel.
The company organizes its work into distinct segments. One focuses on customer-driven formulation and specialty solutions, another centers on facilities in Montana, including a specialty asphalt plant in Great Falls and a renewables facility, and a third houses its branded performance products. A separate corporate segment covers general and administrative costs that are not tied to the other business lines.
Calumet was founded in 1919 and is headquartered in Indianapolis, Indiana. Its shares are listed on the NASDAQ under the ticker CLMT.
Calumet’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 71.9, in the Buying zone, down 3.9 points over five sessions.
Down 3.9 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 64 | +1.0% | +11.9% | ||
| Accumulation | 120 | +0.7% | +3.7% | ||
| Neutral | 444 | +1.4% | +3.9% | ||
| Distribution | 71 | +0.2% | +4.4% | ||
| Selling | 3 | Too few readings yet | |||
Average CLMT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +2.9% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
Calumet trades 16.5% below Gekko Fair Value of $41.10, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Calumet shares are worth, recalculated every trading day.
$41.10
Gekko Fair Value, Nov 14, 2026
16.5% Undervalued
At the end of Aug 2026 the price was 52.7% above the estimate.
No open-market insider purchases were filed for Calumet, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for CLMT in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in CLMT were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Calumet has been buying back its own shares.
From company filings.
0of the funds Gekko tracks hold CLMT.
Calumet reports on Feb 26, 2027, before the open (103 days away), and beat the EPS estimate in 5 of its last 8 reports.
Feb 26, 2027
Expected before the open, 103 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 6, 2026 | $2.91 est $1.63 | $1.68B est $1.34B | −16.8% |
| Aug 7, 2026 | −$0.05 est −$0.23 | $1.45B est $1.12B | +8.6% |
| May 8, 2026 | −$0.64 est −$0.57 | $1.03B est $1.00B | −6.6% |
| Feb 27, 2026 | −$0.43 est −$0.67 | $1.04B est $1.06B | −9.3% |
| Nov 7, 2025 | −$0.21 est −$0.30 | $1.08B est $1.04B | −1.8% |
| Aug 8, 2025 | −$1.70 est −$0.44 | $1.03B est $1.15B | −11.0% |
| May 9, 2025 | −$1.03 est −$0.41 | $993.9M est $922.3M | +10.5% |
| Feb 28, 2025 | −$0.17 est −$0.37 | $949.5M est $866.2M | −10.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Calumet is $55.80, +62.7% from the last close, from 4 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 4 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 9 | Bank of America Securities | — | — |
| Nov 9 | H.C. Wainwright | $75 | +118.7% |
| Oct 21 | Goldman Sachs | $57 | +66.2% |
| Sep 22 | H.C. Wainwright | $75 | +118.7% |
| Sep 2 | H.C. Wainwright | $75 | +118.7% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Calumet averaged +1.4% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.0% | 3 of 5 |
| Next 10 trading days | +5.0% | 4 of 5 |
| Next 15 trading days | +3.3% | 4 of 5 |
| Next 20 trading days | +1.4% | 3 of 5 |
| Next 30 trading days | +0.4% | 3 of 5 |
For scale, CLMT’s typical 20-trading-day move in either direction is about 9.6%.
Calumet’s market cap is $3.02B and revenue of $5.20B over the last twelve months.
Coverage of Calumet this week reads positive: 6 positive, 2 neutral and 0 negative headlines.
Calumet’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| MPCMarathon Petroleum | Accumulation | 4.9% below |
| VLOValero Energy | Accumulation | 0.8% above |
| PSXPhillips 66 | Neutral | 7.9% above |
| DINOHF Sinclair | Accumulation | 5.1% above |
| PBFPBF Energy | Accumulation | 14.4% below |
| DKDelek US | Neutral | 12.4% below |
A peer links to its own page where one exists.
Calumet’s market cap is $3.02B at the Nov 13, 2026 close of $34.30, with 88.09M shares outstanding.
The consensus analyst 12-month price target for Calumet is $55.80, +62.7% from the last close. Of the 4 firms that rated the stock in the last 90 days, 2 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Calumet is undervalued: the Nov 13, 2026 close of $34.30 is 16.5% below Gekko Fair Value of $41.10. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Calumet is expected to report on Feb 26, 2027, before the market opens (103 days away). Analysts expect earnings of $0.92 per share on revenue of $1.21B. Calumet beat the earnings estimate in 5 of its last 8 reports, moving 9.3% on average across the report.
Calumet’s 52-week high is $59.87 and its 52-week low is $17.85; it closed at $34.30 on Nov 13, 2026, +81.2% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.